



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Brief report

Detection of carbapenemases and other mechanisms of enzymatic resistance to β -lactams in *Enterobacteriaceae* with diminished susceptibility to carbapenems in a tertiary care hospital



Marta Gómara*, Ana Isabel López-Calleja, Berta María Pilar Vela Iglesia, Isabel Ferrer Cerón, Antonio Rezusta López, María José Revillo Pinilla

Servicio Microbiología, H. Universitario Miguel Servet, Zaragoza, Spain

ARTICLE INFO

Article history:

Received 22 March 2017

Accepted 11 July 2017

Available online 6 September 2017

Keywords:

Carbapenemase

Antibiotic resistance

Enterobacteriaceae

Molecular biology

ABSTRACT

Introduction: Our objective was to characterize the enzymatic β -lactam resistance in clinical *Enterobacteriaceae* isolates with diminished susceptibility to carbapenems from 2013 to 2014 at Hospital Universitario Miguel Servet.

Material/methods: A total of 63 clinical isolates were analyzed for the presence of carbapenemases (KPC, OXA-48 and MBL), ESBLs and AmpC enzymes by combined disk methods and PCR detection of carbapenemase-encoding and beta-lactamase-encoding genes.

Results: Fifteen isolates had a phenotypic test compatible with carbapenemase production; two of these were confirmed by PCR as OXA-48 producers. ESBL detection was positive in 27 isolates (43%); plasmid-mediated AmpC was detected in nine isolates (14.2%) and derepressed AmpC β -lactamase was present in 18 isolates (28%).

Conclusion: During the study period, the decreased susceptibility to carbapenems in *Enterobacteriaceae* in our area was not due to true carbapenemases but rather to β -lactamase activity (82.5% were ESBL or AmpC producers), probably in combination with decreased permeability of the outer membrane.

© 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Detección de carbapenemasas y otros mecanismos de resistencia enzimáticos a β -lactámicos en enterobacterias con sensibilidad disminuida a carbapenems en un hospital de tercer nivel

RESUMEN

Introducción: Nuestro objetivo fue caracterizar la resistencia enzimática a β -lactámicos en aislados clínicos de *Enterobacteriaceae* con sensibilidad disminuida a carbapenems desde 2013 a 2014 en el Hospital Universitario Miguel Servet.

Material/métodos: Se analizaron un total de 63 aislados clínicos para presencia de carbapenemasas (KPC, OXA-48 y MBL), BLEE y AmpC por método de discos combinados y detección de genes codificantes de carbapenemasas y betalactamasas por PCR.

Resultados: Quince aislados tuvieron un test fenotípico compatible con producción de carbapenemasas; dos de ellos confirmados por PCR como productores de OXA-48. La detección BLEE fue positiva en 27 aislados (43%); se detectó AmpC plasmídica en 9 aislados (14,2%) y se observó β -lactamasa AmpC desreprimida en 18 aislados (28%).

Palabras clave:

Carbapenemasa

Resistencia antibiótica

Enterobacteriaceae

Biología molecular

* Corresponding author.

E-mail address: mgomaralomero@gmail.com (M.M. Gómara-Lomero).

Conclusión: Durante el período de estudio, la sensibilidad disminuida a carbapenems en *Enterobacteriaceae* en nuestra área no se debió a verdaderas carbapenemasas sino a actividad β -lactamasa (82,5% eran productores de BLEE o AmpC) probablemente en combinación con permeabilidad disminuida de la membrana externa.

© 2017 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.
Todos los derechos reservados.

Introduction

Carbapenemase-producing *Enterobacteriaceae* (CPE) has become a public health concern and a threat for the treatment of patients infected with these organisms. Severe infections caused by these bacteria are associated with high mortality rates and rapid nosocomial and community spread, causing important outbreaks in hospitals worldwide.¹ Therapeutic options for the treatment of these infections are limited as these bacteria often acquire a multi-drug resistance profile of difficult control.²

In addition, diagnosis and detection is a challenge for microbiology laboratories, since these enzymes do not always define resistance to carbapenems.^{1,3} A fast and early detection of carbapenemase-producers is essential to carry out successful strategies.

Carbapenem resistance can also be produced in the absence of carbapenemases through the derepression of the constitutive AmpC-encoding gene, the acquisition of exogenous plasmid-borne cephalosporinase- or extended spectrum β -lactamase (ESBL)-genes, or *via* porin permeability reduction.⁴ The aim of this study was to characterize the enzymatic mechanisms of resistance to β -lactams in clinical isolates of *Enterobacteriaceae* showing diminished susceptibility to carbapenems between January 2013 and December 2014 at our hospital.

Material and methods

Selection of bacterial isolates and inclusion criteria

During the study period, 88 clinical isolates of *Enterobacteriaceae* presented diminished susceptibility to carbapenems; among these, only 63 were available for this study. Antimicrobial susceptibility was performed by an automated broth microdilution method (Microscan Walkaway®, Beckman Coulter, Spain) and/or by the disk diffusion method. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for CPE screening and taking into consideration the MIC range of our commercial systems, we included isolates with imipenem MIC ≥ 1 mg/l (Panel NC53 or Panel NM44, Microscan Walkaway®) or ≥ 2 mg/l (Panel NM37, Microscan Walkaway®), meropenem MIC ≥ 1 mg/l and/or ertapenem MIC ≥ 0.5 mg/l.

The imipenem epidemiological cut-off value (ECOFF) according to EUCAST (MIC = 4 mg/l) was taken into account for isolates in which intrinsic decreased susceptibility to imipenem has been described (*Proteus* spp., *Providencia* spp. and *Morganella* spp.). Thus, within these genera, we only included isolates with imipenem MIC ≥ 8 mg/l.

Phenotypic detection of ESBLs, AmpC enzymes and carbapenemases

All isolates were screened for the presence of carbapenemases by combined disk diffusion methods (KPC, OXA-48 and metallo-beta-lactamases (MBL)). Two tests were used depending on the

isolation date. Until August 2013 the method contained a carbapenem (meropenem 10 μ g, Oxoid) alone and in combination with a KPC inhibitor (phenylboronic acid, PBA (Sigma-Aldrich) 400 μ g added), a MBL inhibitor (ethylenediaminetetraacetic acid, EDTA (Sigma-Aldrich), 292 μ g added) and meropenem-PBA-EDTA (400 μ g/292 μ g).⁵

For the interpretation of results, the inhibition zone of the carbapenem disk was compared to the inhibition zones of each of the carbapenem-plus-inhibitor disks. Therefore, production of KPC was suspected when a difference of ≥ 5 mm was observed between meropenem plus PBA as well as meropenem-PBA-EDTA and meropenem. MBL production was suspected when the difference was ≥ 5 mm between meropenem plus DPA as well as meropenem-PBA-EDTA and meropenem. If only a difference of ≥ 5 mm was observed between meropenem-PBA-EDTA and meropenem but were no difference (< 5 mm) with the other carbapenem-plus-inhibitor disks, both KPC and MBL were then suspected.

From September 2013 we used the KPC/MBL and OXA-48 Confirm Kit (RoscoDiagnostica A/S, Taastrup, Denmark) as the routine method for screening of carbapenemases with the aim of detecting OXA-48 carbapenemase-producers and improve the sensitivity. The kit contains disks of meropenem 10 μ g, meropenem plus dipicolinic acid, DPA (MBL inhibitor), meropenem plus cloxacillin (AmpC inhibitor), meropenem plus PBA (KPC inhibitor) and temocillin 30 μ g (OXA-48-like screening).⁶ The tests were interpreted according to manufacturer's instructions as follows. If the meropenem plus DPA disk showed an inhibition zone ≥ 5 mm than that of the meropenem disk, the organism was compatible with MBL activity. An inhibition zone difference ≥ 5 mm between meropenem plus cloxacillin and meropenem alone indicated AmpC activity. If the inhibition zone difference was ≥ 4 mm with meropenem plus PBA but there was no difference (< 4 mm) with the meropenem plus cloxacillin indicated the presence of a KPC enzyme. Negative results of all synergy tests and no zone of inhibition with temocillin 30 μ g were presumptive of an OXA-48 or OXA-48-like enzyme.

Isolates with decreased susceptibility to cephalosporins which fulfilled criteria according to EUCAST breakpoints for ESBLs and/or AmpC screening were phenotypically analyzed, by using combined disk methods with cefotaxime, ceftazidime and/or cefepime plus clavulanic acid⁷ for ESBLs detection and with cefotetan plus boronic acid for AmpC type beta-lactamases detection.⁸

A positive result was interpreted by a difference of ≥ 5 mm in the inhibition zone in the presence of the inhibitor compared with that of the β -lactam alone.

PCR detection of β -lactamase genes

All isolates were analyzed for the presence of carbapenemases by a multiplex PCR assay, according to the method described by Poirel et al.⁹ Sets of primers for the following genes were included: *bla*_{NDM}, *bla*_{VIM}, *bla*_{KPC} and *bla*_{OXA-48}.

In *Escherichia coli*, *Klebsiella* spp. and *Proteus* spp. isolates with ESBLs and/or AmpC positive phenotypic tests, additional

Table 1
Summary of phenotypic tests, PCR analysis, and carbapenem's MICs against the isolates studied ($n = 63$).

Isolate	Phenotypic tests			PCR analysis					MIC (mg/l)		
	AmpC	ESBL	Carbapenemase ^b	<i>bla</i> _{TEM}	<i>bla</i> _{SHV}	<i>bla</i> _{CTX-M} ^c	Plasmid mediated AmpC ^a	Carbapenemase	IPM	MEM	ETP
<i>E. coli</i>											
1EC	NA	–	–	–	–	–	NA	–	8	≤1	1
2EC	+	–	–	–	–	–	CIT	–	≤2	≤1	2
3EC	+	–	–	–	–	–	CIT	–	≤2	≤1	1
4EC	+	–	–	–	–	–	EBC	–	≤1	≤1	1
8EC	–	+	–	+	–	+	–	–	4	8	>1
9EC	–	+	–	+	–	+	–	–	≤1	2	>1
10EC	NA	+	–	–	–	–	NA	–	≤1	ND	1
11EC	–	+	–	+	–	+	–	–	≤2	≤1	1
5EC	+	–	–	–	–	–	CIT	–	≤1	≤1	1
12EC	–	+	–	–	–	+	–	–	≤1	≤1	>1
13EC	–	+	–	+	–	–	–	–	≤1	≤1	>1
6EC	+	–	–	–	–	–	–	–	≤2	≤1	1
14EC	–	+	TMO resistance	–	–	–	–	–	≤1	ND	1
7EC	+	–	Synergy with PBA	–	–	–	CIT	–	≤2	≤1	1
<i>Klebsiella</i> spp.											
16KO	–	–	–	–	–	+	–	–	≤2	≤1	1
19KP	–	–	–	–	–	–	–	–	≤2	4	>4
30KP	+	+	–	–	–	+	EBC	–	≤2	≤1	1
20KP	NA	+	–	+	–	–	NA	–	≤1	≤1	1
21KP	–	+	–	+	–	+	–	–	≤2	2	>4
22KP	–	+	–	+	–	–	–	–	≤1	≤1	1
23KP	–	+	–	+	+	+	–	–	≤2	≤1	2
25KP	–	+	–	+	–	–	–	–	≤2	4	>4
26KP	–	+	–	+	–	+	–	–	≤2	4	>4
27KP	NA	+	–	+	–	+	NA	–	≤2	8	>4
28KP	+	+	–	+	+	+	DHA	–	≤2	≤1	4
29KP	+	+	Synergy with PBA	+	–	–	DHA	–	2	≤1	2
24KP	–	+	Synergy with PBA	–	–	+	–	–	>8	≤1	>4
18KO	–	–	Synergy with PBA	–	–	+	–	–	≤2	2	2
17KO	–	–	Synergy with PBA	–	–	+	–	–	8	>8	>4
31KP	NA	+	TMO resistance	–	–	+	NA	OXA-48-like	≤1	≤1	>1
15KO	–	–	Synergy with PBA	–	–	+	–	–	≤2	4	4
<i>Enterobacter</i> spp.											
32ENT	DR	–	–	–	–	–	–	–	≤1	ND	>1
33ENT	–	–	–	–	–	–	–	–	4	≤1	≤0.5
34ENT	DR	–	–	–	–	–	–	–	≤2	≤1	1
35ENT	+	–	–	+	–	–	–	–	≤2	≤1	2
36ENT	DR	–	–	–	–	–	–	–	≤2	≤1	4
37ENT	DR	–	–	–	–	–	–	–	≤2	≤1	1
38ENT	DR	–	–	–	–	–	–	–	8	>8	>8
39ENT	+	–	–	+	–	–	–	–	≤2	≤1	1
40ENT	–	–	–	–	–	–	–	–	2	≤1	≤1
41ENT	DR	–	–	–	–	–	–	–	2	≤1	≤1
42ENT	+	–	–	–	–	+	–	–	4	≤1	≤0.5
43ENT	DR	–	–	–	–	–	–	–	≤2	≤1	>4
44ENT	DR	–	–	–	–	–	–	–	≤2	≤1	1
45ENT	DR	–	–	–	–	–	–	–	≤1	2	≤1
46ENT	DR	–	–	–	–	–	–	–	≤2	≤1	4
47ENT	DR	–	Synergy with PBA	–	–	–	–	–	≤2	≤1	2
48ENT	DR	–	Synergy with PBA	–	–	–	–	–	≤2	≤1	1
49ENT	DR	–	Synergy with PBA	–	–	–	–	–	≤2	≤1	2
50ENT	DR	–	–	–	–	–	–	–	≤2	≤1	>4
<i>Citrobacter</i> spp.											
51CB	+	–	–	–	–	+	–	–	≤1	1	≤1
52CB	–	–	TMO resistance	–	–	–	–	OXA-48-like	≤1	1	≤1
<i>Morganella</i> spp.											
53MOR	–	–	–	–	–	–	–	–	8	≤1	≤0.5
54MOR	DR	–	–	–	–	–	–	–	8	≤1	≤0.5
55MOR	–	–	–	–	–	–	–	–	8	≤1	≤0.5
56MOR	–	–	–	–	–	–	–	–	8	≤1	≤0.5
57MOR	DR	–	TMO resistance	–	–	–	–	–	8	≤1	≤0.5
<i>Serratia</i> spp.											
58SER	–	–	–	–	–	–	–	–	2	≤1	≤0.5
59SER	–	–	–	–	–	–	–	–	4	≤1	1
60SER	DR	–	Synergy with PBA	–	–	–	–	–	≤2	4	2
61SER	DR	–	Synergy with PBA and TMO resistance	–	–	–	–	–	≤2	≤1	>4

Table 1 (Continued)

Isolate	Phenotypic tests			PCR analysis					MIC (mg/l)		
	AmpC	ESBL	Carbapenemase ^b	<i>bla</i> _{TEM}	<i>bla</i> _{SHV}	<i>bla</i> _{CTX-M} ^c	Plasmid mediated AmpC ^a	Carbapenemase	IPM	MEM	ETP
<i>Proteus</i> spp.											
62PROT	–	–	–	–	–	–	CIT	–	8	≤1	≤0.5
63PROT	–	–	–	–	–	–	–	–	8	≤1	≤0.5

ETP: ertapenem; IPM: imipenem; MEM: meropenem; TMO: temocillin; –: absence; +: presence; DR: derepressed AmpC; ND: not determined; NA: not available; PBA: phenyl-boronic acid.

EC: *Escherichia coli*; KO: *Klebsiella oxytoca*; KP: *Klebsiella pneumoniae*; ENT: *Enterobacter* spp.; CB: *Citrobacter* spp.; MOR: *Morganella* spp.; SER: *Serratia* spp.; PROT: *Proteus* spp.

^a Primer pair amplified, families of AmpC included not sequenced; CIT includes LAT-1 to LAT-4, CMY-2 to CMY-7, BIL-1; DHA includes DHA-1, DHA-2; EBC includes MIR-1T, ACT-1.

^b Synergy observed/temocillin resistance.

^c CTX-M primer pair also target chromosomal K1 enzyme gene present in all *K. oxytoca* isolates (15KO, 16KO, 17KO, 18KO).

betalactamases encoding genes were investigated: *bla*_{SHV}, *bla*_{TEM} and *bla*_{CTX-M}¹⁰ and six sets of AmpC-specific primers (ACC, FOX, CMY/MOX, DHA, LAT/CMY/BIL and ACT/MIR¹¹). In chromosomal AmpC producers with phenotypic ESBL detection, *bla*_{SHV}, *bla*_{TEM} and *bla*_{CTX-M}¹⁰ genes were also analyzed.

DNA extraction was performed using PrepMan® Ultra Sample Preparation Reagent (Applied Biosystems) according to the manufacturer's instructions. PCR products were visualized by electrophoresis in 2% agarose gels stained with GelRed™ Nucleic Acid Stain 10,000 in water (Biotium).

Results

A total of 88 non-duplicated clinical isolates of *Enterobacteriaceae* showed reduced susceptibility to carbapenems, 0.4% over 20,774 *Enterobacteriaceae* isolated during the study period; among the 88 isolates, 63 were available to be included in the study. The specimens were collected from 22 urine samples, 15 respiratory secretions, 10 wound samples and biological fluids, 9 blood cultures and 7 screening nasal, rectal and/or inguinal swabs for epidemiological surveillance. At the time of isolation, 55.5% of the patients ($n=35$) were hospitalized, 38% were outpatients ($n=24$) and 6.3% ($n=4$) were admitted at the emergency department.

The isolates belonged to the following species: *Enterobacter* spp. ($n=19$, 30%), *Klebsiella* spp. ($n=17$, 27%), *E. coli* ($n=14$, 22%), *Morganella* spp. ($n=5$, 8%), *Serratia* spp. ($n=4$, 7%), *Citrobacter* spp. ($n=2$, 3%) and *Proteus* spp. ($n=2$, 3%).

Fifteen isolates had a phenotypic test compatible with a carbapenemase production (synergy with inhibitors employed and/or temocillin resistance). Among them, ten isolates showed synergy with PBA as possible KPC producers and one additional isolate also showed temocillin resistance, most of them corresponded to AmpC β -lactamases inhibited with PBA (Table 1). Four isolates presented temocillin resistance, being two of them confirmed by PCR as OXA-48 producers; the production of carbapenemase was confirmed at the National Reference Laboratory in Spain (*Klebsiella pneumoniae* 31KP and *Citrobacter koseri* 52CB) accounting for 3.17% of the strains in this study.

Phenotypic ESBL detection was positive in 27 isolates; beta-lactamase-encoding genes were detected in 25 of them (39.6%), being *bla*_{TEM} detected in fifteen isolates (60%, 15/25), *bla*_{CTX-M} in fourteen (56%, 14/25) and *bla*_{SHV} in two (8%, 2/25). Eight isolates combined more than one resistance beta-lactamase gene (Table 1).

In 14.2% ($n=9$) of the isolates, plasmid-mediated AmpC beta-lactamases were detected, most of them ($n=5$) amplified with CIT primers (families LAT-1 to LAT-4, CMY-2 to CMY-7 and BIL-1). Derepressed AmpC β -lactamase, according to reduced susceptibility to third-generation cephalosporins (cefotaxime, ceftaxone and ceftazidime) and monobactams (aztreonam)¹² was present in 18 isolates (28%). No beta-lactamase genes were detected by PCR in three isolates (*K. pneumoniae* 19KP, *E. coli* 1EC and *Proteus*

vulgaris 63PROT). Isolate 19KP showed a cefotaxime MIC = 2 mg/l, ceftazidime MIC = 16 mg/l, cefepime MIC >16 mg/l, aztreonam MIC = 8 mg/l, meropenem MIC = 4 mg/l and ertapenem MIC >4 mg/l and no AmpC or ESBL confirmation was observed by phenotypic and genotypic methods. Isolate 1EC was susceptible to cephalosporins (no ESBL or AmpC-type) but showed high carbapenem MICs (imipenem MIC = 8 mg/l, ertapenem MIC = 1 mg/l), and isolate 63PROT showed resistance to cefotaxime (MIC >32 mg/l), compatible with CumA beta-lactamase, and to imipenem (MIC = 8 mg/l) (Fig. 1).

According to EUCAST breakpoints, among our isolates analyzed, 20.6% (13/63) were non-susceptible to imipenem, 14.2% (9/63) to meropenem, and 84.1% (53/63) to ertapenem. Two isolates (*K. oxytoca* 17KO with hyperproduction of the chromosomally encoded K1 β -lactamase and *Enterobacter* spp., 38ENT showing derepressed chromosomal AmpC) were resistant to all three antibiotics assayed (Table 1).

Discussion

The emergence of CPE as well as the resistance to carbapenems is a cause of public health concern causing community and nosocomially acquired-infections. This study contributes to clarify the mechanisms involved in reduced susceptibility to carbapenems. Despite several outbreaks described around our country, CPE have not been detected in our hospital until 2014 where two cases of OXA-48-like CPE were confirmed.

Our results show that most of our carbapenem non-susceptible isolates (82.5%) were ESBL or AmpC producers, probably combined with decreased permeability of the outer membrane (porin loss or mutation of the porin-coding sequence) and/or overexpression of efflux pumps. The contribution to carbapenem resistance by loss of porins has been widely described.^{13–15} Unfortunately, in our laboratory it is not possible to analyze this mechanism of resistance and this is one limitation of our work. Further studies will be needed to analyze this mechanism. In contrast, the role of efflux pumps as contributors to resistance to carbapenems in *Enterobacteriaceae* is infrequent.¹⁶

Most of the AmpC producers showed PBA synergy in the carbapenemase phenotypic detection test, a limitation that can be solved by using Mueller Hinton cloxacillin agar.⁶

All isolates studied expressed a β -lactam resistance mechanism that could be detected or explained, except for three isolates in which no PCR amplicons for carbapenemases or beta-lactamases were obtained. These strains could have another resistance mechanisms responsible for carbapenem resistance, like an expression of different ESBL encoding genes, or a blocker of the porin channel as it has been reported.⁴

Previous studies^{4,16} reported an ESBL prevalence close to 50% among isolates with decreased susceptibility to carbapenems; in our case ESBL were phenotypically detected in 42.8% of the isolates




Fig. 1. Distribution of resistance mechanisms of the isolates studied.

and in 39.6% by PCR amplification of the beta-lactamase-encoding genes. It was not the aim of this study to analyze the families to which these ESBL and/or plasmid-mediated AmpC isolates with a negative PCR belonged; this strategy would require complete gene sequencing analysis. Nevertheless, taking into account the results obtained, 52% of the phenotypic ESBL isolates belonged to CTX-M family, which has been described as the most prevalent worldwide,¹⁷ and most of AmpC amplification products observed could be according to the prevalent family in our area CMY-2.^{17,18}

In our study, nineteen chromosomal AmpC isolates showed resistance to cefepime. This resistance could be due to AmpC hyperproduction associated with porin loss or to AmpC with hydrolytic activity against cefepime, as previously reported.¹⁹ The fact that CPE may show a low level of resistance or even *in vitro* susceptibility to carbapenems (not detectable with commercial antimicrobial susceptibility testing panels, as in our study) suggests that active surveillance of these enzymes is critical in order to avoid misdiagnosis and/or underestimation of its prevalence.

The phenotypic detection of carbapenemases (mainly OXA-48-like carbapenemases) remains challenging, due to the low level of resistance sometimes presented, and the possibility of other resistance mechanisms like ESBL or AmpC combined with porine loss. Nevertheless, given the existing situation in surrounding areas it is necessary to strengthen the surveillance, especially in patients with risk factors.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

We thank Marina Oviaño for advice and support given.

References

- Nordmann P, Naas T, Poirel L. Global spread of carbapenemase producing Enterobacteriaceae. *Emerg Infect Dis*. 2011;17:1791–8.
- Oteo J, Saez D, Bautista V, Fernández-Romero S, Hernández-Molina JM, Pérez-Vázquez M, et al. Carbapenemase-producing Enterobacteriaceae in Spain in 2012. *Antimicrob Agents Chemother*. 2013;57:6344–7.
- Hrabák J, Chudáková E, Papagiannitsis C. Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic microbiological laboratories. *Clin Microbiol Infect*. 2014;20:839–53.
- Wozniak A, Villagra NA, Undabarrena A, Gallardo N, Keller N, Moraga M, et al. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. *J Med Microbiol*. 2012;61:1270–9.
- Tsakris A, Poulou A, Pournaras S, Voulgari E, Vriani G, Themeli-Digalaki K, et al. A simple phenotypic method for the differentiation of metallo-β-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. *J Antimicrob Chemother*. 2010;65:1664–71.
- Maurer FP, Castelberg C, Quiblier C, Bloemberg GV, Hombach M. Evaluation of carbapenemase screening and confirmation tests with Enterobacteriaceae and development of a practical diagnostic algorithm. *J Clin Microbiol*. 2015;53:95–104.
- CLSI. Performance standards for antimicrobial susceptibility testing. 25th ed. Wayne, PA: CLSI supplement M100S, Clinical and Laboratory Standards Institute; 2015.
- Coudron PE. Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in *Klebsiella* spp., *Escherichia coli* and *Proteus mirabilis*. *J Clin Microbiol*. 2005;43:4163–7.
- Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis*. 2011;70:119–23.
- Monstein HJ, Ostholm-Balkhed A, Nilsson MV, Nilsson MV, Dornbusch K, Nilsson LE, et al. Multiplex PCR amplification assay for the detection of bla_{SHV}, bla_{TEM} and bla_{CTX-M} genes in Enterobacteriaceae. *APMIS*. 2007;115:1400–8.
- Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol*. 2002;40:2153–62.
- Livermore DM. Beta-lactamases in laboratory and clinical resistance. *Clin Microbiol Rev*. 1995;8:557–84.
- Martínez-Martínez L, Pascual Á, Hernández-Allés S, Álvarez-Díaz D, Suárez AI, Tran J, et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 1999;43:1669–73.
- Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–06. *J Antimicrob Chemother*. 2008;62 Suppl. 2:41–54.
- Papaparaskevas J, Pantazatou A, Stefanou I, Mela V, Galatidis N, Avlami A. Differences in the evolution of imipenem susceptibility among *Klebsiella pneumoniae*

- and *Escherichia coli* isolates during a 6-year period in a tertiary care hospital. *Int J Antimicrob Agents*. 2007;29:197–200.
16. Lastra De V, Rivas LM, Silva F, Ulloa MT, Pinto ME. Detection of serinocarbapenemases Class A and other mechanisms of enzymatic resistance to β -lactams in enterobacteria strains with diminished susceptibility to carbapenems isolated of patients in a university hospital. *Rev Chil Infectol*. 2014;31:682–8.
 17. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extended-spectrum β -lactamase-producing Enterobacteriaceae in Europe. *Clin Microbiol Infect*. 2008;14 Suppl. 1:144–53.
 18. Seral C, Gude MJ. Emergencia de β -lactamasas AmpC plasmídicas (pAmpC ó cefamicinasas): origen, importancia, detección y alternativas terapéuticas. *Rev Esp Quim*. 2012;25:89–99.
 19. Fernández-Cuenca F, Rodríguez-Martínez JM, Martínez-Martínez L, Pascual A. In vivo selection of *Enterobacter aerogenes* with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC β -lactamase. *Int J Antimicrob Agents*. 2006;27:549–52.